PBS/RPBS cost implications of trends and guideline recommendations in the pharmacological management of hypertension

Ben D Ewald and Brita A Pekarsky
Med J Aust 2002; 176 (4): . || doi: 10.5694/j.1326-5377.2002.tb04357.x
Published online: 18 February 2002

To the Editor: The article by Nelson et al1 estimates Pharmaceutical Benefits Scheme and Repatriation Pharmaceutical Benefits Scheme (PBS/RPBS) savings if hypertensive patients on monotherapy were prescribed the agents recommended in guidelines; however, the analysis contains algebraic errors and insufficient sensitivity analyses. The question of excessive costs through the use of expensive agents for which there is no evidence of increased benefit for most patients is an important one, but the estimates of extent of overuse should be methodologically sound. The three main concerns we have with the paper's estimates are as follows:

  • 1 Centre for Clinical Epidemiology and Biostatistics, University of Newcastle, Newcastle, NSW.
  • 2 Department of General Practice, University of Adelaide, Adelaide, SA.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.